The present invention relates to a process for the preparation of crosslinked hyaluronic acid butyrate or crosslinked hyaluronic acid butyrate-formate or an acceptable salt thereof, wherein the process comprises the crosslinking reaction of hyaluronic acid butyrate or hyaluronic acid butyrate-formate or a pharmaceutically acceptable salt thereof in an organic solvent with a carboxyl activating reagent, characterized in that the hyaluronic acid butyrate or hyaluronic acid butyrate-formate or pharmaceutically acceptable salt thereof is a mixture of a high-molecular-weight polysaccharide and a low-molecular-weight polysaccharide.

A PEG-lipid is produced by mixing a cation-PEG-lipid comprising at least one amino group with a sulfated glycosaminoglycan comprising at least one carbonyl group to form a Schiff base intermediate. A reducing agent is added to the Schiff base intermediate to form a sulfated glycosaminoglycan-PEG-lipid. The sulfated glycosaminoglycan-PEG-lipid can be used to biological tissue against thromboinflammation. Coating of biological tissue with the sulfated glycosaminoglycan-PEG-lipid can be done in a single step process and does not cause any significant cell aggregation.

A PEG-lipid is produced by mixing a cation-PEG-lipid comprising at least one amino group with a sulfated glycosaminoglycan comprising at least one carbonyl group to form a Schiff base intermediate. A reducing agent is added to the Schiff base intermediate to form a sulfated glycosaminoglycan-PEG-lipid. The sulfated glycosaminoglycan-PEG-lipid can be used to biological tissue against thromboinflammation. Coating of biological tissue with the sulfated glycosaminoglycan-PEG-lipid can be done in a single step process and does not cause any significant cell aggregation.

The present invention provides refillable drug delivery systems, as well as methods of refilling the systems, and methods of using them to treat diseases.

Disclosed herein is the use of a hyaluronan (HA) conjugate for treating cancer. Also disclosed herein is the use of a hyaluronan conjugate for treating cancer. The hyaluronan conjugate is a nimesulide-HA conjugate having a monosaccharide or one to four disaccharide units of the hyaluronic acid.

Disclosed herein is the use of a hyaluronan (HA) conjugate for treating cancer. Also disclosed herein is the use of a hyaluronan conjugate for treating cancer. The hyaluronan conjugate is a nimesulide-HA conjugate having a monosaccharide or one to four disaccharide units of the hyaluronic acid.

Provided herein are bioconjugates comprising a backbone and at least one branched or unbranched peptide having at least one collagen-binding unit covalently bonded thereto via a spacer and methods of use thereof.

Provided herein are bioconjugates comprising a backbone and at least one branched or unbranched peptide having at least one collagen-binding unit covalently bonded thereto via a spacer and methods of use thereof.

The present disclosure relates to nanoparticles and methods for polynucleotide transfection.

Disclosed herein is a hyaluronan conjugate, which includes a hyaluronic acid (HA), a sex hormone, and a linker for coupling one of the disaccharide units of the HA and the sex hormone. Also disclosed herein are the uses of the hyaluronan conjugate in treating or preventing neurodegenerative diseases.